Incoming Novartis CEO On $475,000 Cancer Therapy:'No Question That The List Price Raises Eyebrows '

Incoming CEO at Swiss drugmaker Novartis, Vas Narasimhan, said he isn ’t interested in following the herd in drug development.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

This study investigated the presence of Streptococci, Staphylococci, aerobic gram negative bacteria (AGNB), Candida and bacterial endotoxins in the oral cavities of patients receiving chemo- and/or radiotherapy for cancer.MethodsSamples of oral cavity rinse were collected from 100 patients on cancer treatment and 70 healthy individuals. Demographic and clinical data were recorded. Samples were cultured onto various agar plates for qualitative and quantitative analysis and tested for the presence of endotoxin. Results were analysed using the Mann-Whitney and chi-square tests.ResultsIn cancer patients, S. aureus counts were ...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
Overexpression of IQGAP1 promotes the angiogenesis of esophageal squamous cell carcinoma through the AKT and ERK‑mediated VEGF‑VEGFR2 signaling pathway. Oncol Rep. 2018 Jul 11;: Authors: Li CH, Sun XJ, Niu SS, Yang CY, Hao YP, Kou JT, Li XZ, Wang XX Abstract Angiogenesis is crucial for the progression of esophageal squamous cell carcinoma (ESCC). Anti‑angiogenesis by targeting important molecules has been considered as one of the most promising and efficient strategy for cancer therapy. Recent studies have demonstrated that the IQ‑domain GTPase activating protein 1 (IQGAP1) plays critical ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Kalimuthu S, Zhu L, Oh JM, Gangadaran P, Lee HW, Baek SH, Rajendran RL, Gopal A, Jeong SY, Lee SW, Lee J, Ahn BC Abstract Mesenchymal stem cells (MSCs) show therapeutic effects in various types of diseases. MSCs have been shown to migrate towards inflamed or cancerous tissues, and visualized after sacrificing the animal. MSCs are able to deliver drugs to target cells, and are an ideal candidate for cancer therapy. The purpose of this study was to track the migration of MSCs in tumor-bearing mice; MSCs were also used as drug delivery vehicles. Human breast cancer cells (MDA-MB-231) and anaplastic thyroid ca...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Publication date: Available online 17 July 2018Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Duarte de Melo-Diogo, Rita Lima-Sousa, Cátia G. Alves, Elisabete C. Costa, Ricardo O. Louro, Ilídio J. CorreiaAbstractGraphene family nanomaterials’ (GFN) ability to interact with near-infrared light has propelled their application in cancer photothermal therapy. Furthermore, the graphitic lattice of GFN can adsorb different types of molecules, which has motivated their use in cancer drug delivery. However, the direct application of GFN in cancer therapy is severely hindered by their poor colloidal st...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
This study identified a previously unrecognized regulatory axis between AHR and polyamine metabolism and discovered clofazimine as an inhibitor of AHR and a potentially clinically-relevant anti-multiple myeloma agent.RNA-seq: human multiple myeloma MM1S and human normal fibroblasts WI38 cells -/+ CLF 2-4uM for 24hrs; -/+ shAHR
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
(Wiley) Previous research has shown that cannabinoids can help lessen side effects of anti-cancer therapies. Now a new British Journal of Pharmacology review has examined their potential for the direct treatment of cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
AbstractIdentification of the driver mutations in cancer has resulted in the development of a new category of molecularly targeted anti-cancer drugs. However, as was the case with conventional chemotherapies, the effectiveness of these drugs is limited by the emergence of drug-resistant variants. While most cancer therapies are given in combinations that are designed to avoid drug resistance, we discuss here therapeutic approaches that take advantage of the changes in cancer cells that arise upon development of drug resistance. This approach is based on notion that drug resistance comes at a fitness cost to the cancer cell...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
SummaryMicrotubule as an important target in the cancer therapy was used to design novel tubulin polymerization inhibitors. Sulfanilamide-1,2,3-triazole hybrids were designed by a molecular hybridization strategy and their antiproliferative activity against three selected cancer cell lines (BGC-823, MGC-803 and SGC-7901) were evaluated. All sulfanilamide-1,2,3-triazole hybrids displayed potent inhibitory activity against all cell lines. In particular, compound10b showed the most excellent inhibitory effect against MGC-803 cells, with an IC50 value of 0.4 μM. Cellular mechanism studies elucidated that10b induced apoptosi...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Treatment costs for the immunotherapy can run to more than $1 million. Some state Medicaid programs aren't paying for the treatment, and Medicare's complicated payment rates have hospitals worried.(Image credit: Fanatic Studio/Collection Mix: Subjects RF/Getty Images)
Source: NPR Health and Science - Category: Consumer Health News Authors: Source Type: news
Conclusion: Our results indicate that SirT1 regulates apoptosis and radiation sensitization in lung cancer cell lines A549 and H460 via the SirT1/NF- κB/Smac pathway.Cell Physiol Biochem 2018;48:304 –316
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Pharmaceuticals | Switzerland Health